Lilly declares third-quarter 2025 dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Lilly declares third-quarter 2025 dividend
June 25, 2025 5:11 AM EDT
Citi analyst Geoff Meacham reiterated a Buy rating and $1,190.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Given compelling data, Lilly and Novo have reframed obesity as a treatable disease, not just a lifestyle/behavior-based condition. The obesity paradigm should further... More
June 23, 2025 12:14 PM EDT
Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,133.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "One of the side effects of the dramatic weight loss of GLP-1 based medications is that people also lose muscle/lean body mass. LLY, REGN, BHVN and other companies are developing drugs targeting the activin receptor pathway with the goal of preventing/slowing muscle mass loss. LLY's program broadly blocks the receptors (and hence activins, myostatin, and GDF11 ligands simultaneously), while REGN is focused on selectively blocking two ligands (myostatin and activin A)... More
